# Absci
> Absci is a generative AI drug creation company that combines AI with synthetic biology to discover and develop novel biologics. The company's platform designs and validates new drug candidates, specifically antibodies, with the goal of increasing the success rate and speed of drug discovery.
- URL: https://optimly.ai/brand/absci
- Slug: absci
- BAI Score: 72/100
- Archetype: Challenger
- Category: Biotechnology
- Last Analyzed: April 10, 2026
- Part of: Independent (https://optimly.ai/brand/independent)
## Also Referenced By
- Ginkgo Bioworks (https://optimly.ai/brand/ginkgo-bioworks)
## Buyer Intent Signals
Problems: Traditional Wet-Lab Discovery: Internal R&D teams attempting to identify antibody candidates using traditional wet-lab trial and error. | CROMO Biology Services: Hiring specialized contract research organizations to perform traditional drug discovery services. | Legacy Data Management: Managing discovery data via spreadsheets and legacy local databases without AI integration.
Solutions: generative AI for antibody discovery | de novo protein design companies | AI drug creation platform | best AI biotech stocks | AstraZeneca AI discovery partner